New Zealand markets close in 1 hour 27 minutes
  • NZX 50

    10,995.47
    -2.45 (-0.02%)
     
  • NZD/USD

    0.6298
    -0.0006 (-0.09%)
     
  • NZD/EUR

    0.5949
    +0.0000 (+0.01%)
     
  • ALL ORDS

    6,918.40
    +24.80 (+0.36%)
     
  • ASX 200

    6,728.90
    +22.90 (+0.34%)
     
  • OIL

    110.67
    +1.10 (+1.00%)
     
  • GOLD

    1,827.00
    +2.20 (+0.12%)
     
  • NASDAQ

    12,008.24
    -97.61 (-0.81%)
     
  • FTSE

    7,258.32
    +49.51 (+0.69%)
     
  • Dow Jones

    31,438.26
    -62.42 (-0.20%)
     
  • DAX

    13,186.07
    +67.94 (+0.52%)
     
  • Hang Seng

    22,017.18
    -212.34 (-0.96%)
     
  • NIKKEI 225

    26,830.69
    -40.58 (-0.15%)
     
  • NZD/JPY

    85.1650
    -0.1760 (-0.21%)
     

Correction: Sensus Healthcare to Participate in the H.C. Wainwright Global Investment Conference

·1-min read
Sensus Healthcare, Inc.
Sensus Healthcare, Inc.

BOCA RATON, Fla, May 23, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be participating in the H.C. Wainwright Global Investment Conference taking place virtually and in-person at the Fontainebleau Miami Beach May 23-26, 2022.

Sensus management will deliver a corporate presentation on May 24 at 9:30 a.m. Eastern time, and the live and archived presentation will be available on the Company’s website here.  In addition, Michael Sardano, president and general counsel, and Javier Rampolla, chief financial officer, will be holding one-on-one meetings with the investment community both virtually and in-person at the conference.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100, SRT-100+ and SRT-100 Vision systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit www.sensushealthcare.com.

Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

#   #   #


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting